Multipole Myeloma Research Foundation (MMRF) and Multiple Myeloma Research Consortium (MMRC) Mourns Loss of Frederick Joseph

Dedicated Board Member Succumbs to Multiple Myeloma at Age 72

December 30, 2009

 The Multiple Myeloma Research Foundation (MMRF) and Multiple Myeloma Research Consortium (MMRC) are deeply saddened by the loss of MMRF and MMRC Board Member and dear friend Frederick Joseph. He passed on November 27, 2009, following a courageous battle with multiple myeloma, an uncommon and incurable blood cancer.

“Fred was one of the most heroic and inspirational individuals I have known. We will miss his sage advice, his thoughtful guidance, and his enduring kindness,” said Kathy Giusti, founder and CEO of the MMRF, and a multiple myeloma patient. “Our thoughts and prayers are with his wife, Linn, and his family and friends, as they cope with this terrible loss.”

Joseph joined the MMRF and MMRC Board of Directors in 2008 shortly after being diagnosed with multiple myeloma. 

About Multiple Myeloma
Multiple myeloma is an incurable blood cancer with one of the lowest survival rates of all cancers. It is the second most common blood cancer after non-Hodgkin’s lymphoma. In the United States, there are an estimated 59, 203 people living with multiple myeloma. In 2009, an estimated 20, 580 people were diagnosed with multiple myeloma and 10, 590 people died from the disease.

About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $130 million since its inception to fund more than 120 laboratories worldwide. An outstanding 93 percent of funds raised go toward research and related programming. The MMRF has supported 40 new compounds and approaches in clinical trials and pre- clinical studies and has facilitated 22 clinical trials through its sister organization, the Multiple Myeloma Research Consortium (MMRC). For more information about the MMRF, visit www.themmrf.org.

Media Contact: Terri Clevenger, 203-227-0209, tclevenger@continuumhealthcom.com